News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation
The CDCCs are strategically positioned in regions identified as high-impact areas
The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
iSolveSM information on demand is the result of our focus on customer relationship
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Subscribe To Our Newsletter & Stay Updated
